Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

The expression of MICA/B cell-surface proteins is induced by cellular stress ... or other attributes to warrant further ...

Despite the diverse nature of obesity, there is compelling genetic, clinical, and experimental evidence that endorses the ...

In the healthcare sector, companies often work towards crucial events or milestones that can drive significant changes in a ...

Q3 2024 Earnings Call Transcript November 8, 2024 Y-mAbs Therapeutics, Inc. reports earnings inline with expectations.

When your number of B cells goes down, your amount of T cells that cause inflammation goes down, too. At the same time, your level of something called regulatory T cells goes up. Regulatory T ...

We continue to target regulatory submission before the end of the year in the ... for the evaluation of Yescarta for newly diagnosed high-risk large B-cell lymphoma who have a positive PET scan after ...

In the 1970s, Yunde Hou identified a new type of interferon-α and 10 years later successfully put a recombinant protein on the market for the treatment of chronic hepatitis B. After the Cultural ...

Monte Rosa Therapeutics, Inc. secures $150M partnership with Novartis for immune treatments. Click for my updated look at ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...